In a landmark decision that’s poised to transform chronic hand eczema (CHE) management, the U.S. Food and Drug Administration (FDA) has approved delgocitinib cream 2%, making it the first and only therapy specifically indicated for moderate-to-severe CHE in adults.
For clinicians and dermatology leaders, this approval represents more than a new tool in the therapeutic toolbox. It signals a renewed prioritization of under-addressed inflammatory skin conditions and sets a precedent for the future of targeted, topical therapies.
Filling a Long-Standing Therapeutic Gap
CHE affects nearly 10% of the adult population globally, yet it has long existed in a gray zone of treatment. Management typically relies on off-label topical steroids or systemic immunosuppressants, each with limitations and long-term risks. For dermatologists, treating CHE has often meant balancing symptom relief with safety concerns, particularly for patients with persistent or relapsing disease.
With delgocitinib cream 2%, clinicians now have an FDA-approved topical option specifically tested and validated for CHE. In pivotal phase 3 trials (DELTA 1 and DELTA 2), Anzupgo demonstrated significant improvements in clinical signs, itch, and pain—symptoms that can impair daily functioning, quality of life, and even career continuity, particularly for individuals in manual labor or health care settings.
Industry Implications: The Rise of Targeted Topical Immunomodulators
Anzupgo’s approval also marks the first time a topical pan-JAK inhibitor has been approved for any skin condition in the U.S., opening the door to broader applications of this class of drugs in dermatology. This sets a new regulatory precedent for JAK inhibitors delivered via the skin, potentially expanding their use in other localized inflammatory disorders where systemic delivery carries greater risk.
As safety remains top of mind for prescribers and patients alike, Anzupgo’s tolerability profile, marked by low rates of adverse events and minimal systemic absorption, could make it a model for future anti-inflammatory agents that bypass the systemic burden altogether.
The Business of Innovation: Why This Approval Matters
For pharmaceutical and biotech stakeholders, this approval underscores the viability of innovation in niche dermatologic diseases. Rather than only competing in crowded biologic markets (e.g., psoriasis, atopic dermatitis), Anzupgo’s success demonstrates the industry’s growing interest in underserved indications with high unmet needs and strong patient advocacy potential.
As more data emerge from real-world use and post-marketing surveillance, payers and providers alike will be watching to see how Anzupgo performs outside of the clinical trial setting, particularly in diverse patient populations with varying occupational exposures and disease chronicity.
What’s Next for Dermatology?
The approval of Anzupgo is a clear signal: dermatology is entering a new age of specificity. As drug development continues to align more closely with pathophysiology, rather than relying solely on broad immunosuppression, clinicians are gaining new, disease-targeted options that promise not just efficacy, but personalization.
For patients with CHE, this isn’t just the first FDA-approved option—it’s a long-overdue acknowledgment of their disease burden.
And for the dermatology community, it’s a call to continue pushing innovation toward the conditions that have waited too long for the spotlight.
Sources:
